Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: Anesthesiology. 2019 Jun;130(6):958–970. doi: 10.1097/ALN.0000000000002668

Table 4.

Summary of 6-week change scores in quality of life and neurological outcomes measures.

Variable Lidocaine (mean ± SD) Placebo (mean ± SD) P-Value*
Quality of Life CESD (−) 0.57 ± 7.5 0.16 ± 8.3 >0.999
DASI (+) −10.98 ± 15.4 −11.67 ± 16.8 >0.999
STAI (−) −7.12 ± 12.1 −6.31 ± 11.4 >0.999
Symptoms Limitation (−) −0.67 ± 4.0 −0.80 ± 3.9 >0.999
OARS-IADL (−) 2.46 ± 4.2 2.10 ± 3.9 >0.999
Cognitive Difficulties (−) −3.00 ± 14.6 −3.21 ± 15.9 >0.999
Social Activities (−) 0.95 ± 3.4 1.59 ± 3.2 0.084
Social Support (+) 1.23 ± 14 −0.49 ± 13.9 0.814
Work Activities (−) 2.71 ± 4.9 3.00 ± 4.3 >0.999
General Health Perception (−) −0.004 ± 1.3 −0.03 ± 1.2 >0.999

Neurologic Outcomes NIHSS (−) 0.05 ± 0.5 0.04 ± 0.5 >0.999
WPNS (+) 0.04 ± 1.1 −0.01 ± 1.3 >0.999

A minus sign (−) indicates that a lower score is better; a plus sign (+) indicates that a higher score is better. CESD: Center for Epidemiologic Studies – Depression Scale, DASI: Duke Activity Status Index, STAI: State Trait Anxiety Inventory, OARS-IADL: Duke Older American Resources Services Procedures – Instrumental Activities of Daily Living, NIHSS: National Institutes of Health Stroke Scale, WPNS: Western Perioperative Neurologic Scale.

*

Adjusted for multiple comparisons.